IMP 321

Drug Profile

IMP 321

Alternative Names: CD223; EDP 202; hLAG-3Ig; ImmuFact IMP321; IMP321; LAG-3 - Prima Biomed; LAG-3Ig; sLAG-3; Soluble recombinant human LAG-3 protein

Latest Information Update: 30 Mar 2017

Price : $50

At a glance

  • Originator Immutep
  • Developer Immutep; Prima BioMed
  • Class Adjuvants; CD antigens; Immunoglobulins; Recombinant fusion proteins
  • Mechanism of Action Antigen presenting cell stimulants; T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Breast cancer
  • Phase I Malignant melanoma
  • No development reported Renal cell carcinoma

Most Recent Events

  • 23 Mar 2017 Positive preliminary efficacy data from the phase I TACTI-mel trial in Malignant melanoma released by Prima BioMed
  • 28 Feb 2017 Prima BioMed has patent protection for IMP 321 in USA
  • 19 Dec 2016 Competent Authority and Ethics Committee, UK approves clinical trial application for IMP 321 in Breast cancer
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top